Skip to main content

High-dose Chemotherapy and Stem Cell Transplant for Childhood Leukemia

A stem cell transplant (SCT), also known as a bone marrow transplant or hematopoietic stem cell transplant), can sometimes be used to help improve the chances of curing childhood leukemia.

How SCT is different from solid organ transplants

Compared to solid organ transplants that work immediately, SCT instead “plants the seeds” that allow new bone marrow to grow and make blood cells. First, high-dose chemotherapy destroys the bone marrow (where new blood cells are formed) and the leukemia. Then, SCT replaces the blood-forming stem cells and immune system in the bone marrow that were killed by the chemo. It can take weeks to months after new blood stem cells are given before the bone marrow is able to make all of the blood cells on its own.

To learn about how a SCT is done, see Stem Cell Transplant for Cancer.

Allogeneic stem cell transplant

For childhood leukemias, the type of transplant used is known as an allogeneic SCT. In this type of transplant, the blood-forming stem cells are donated from another person.

The donor’s tissue type (also known as the HLA type) should match the patient’s tissue type as closely as possible to help prevent the risk of major problems with the transplant. Tissue type is based on certain substances on the surface of cells in the body. The closer the tissue match between the donor and the recipient, the better the chance the transplanted cells will “take” and begin making new blood cells. This is different from a person’s blood type (also known as ABO or Rh).

The donor may be a sibling with the same tissue type as the patient. Other times, it can be an HLA-matched, unrelated donor—a stranger who has volunteered to donate blood-forming stem cells. Sometimes umbilical cord blood stem cells are used. These stem cells come from blood drained from the umbilical cord and placenta after a baby is born and the umbilical cord is cut. (This blood is rich in stem cells.) Whatever their source, the stem cells are then frozen and stored until they are needed for the transplant.

When a SCT might be used

Whether a SCT may be used in treatment depends on the type of leukemia.

In ALL, SCT might be used in children in some high-risk groups whose leukemia is more likely to come back after the initial (induction) chemo. In this case, the transplant is done after the induction chemo puts the leukemia into remission.

SCT might also be an option if the leukemia does not respond well to initial treatment, or if it relapses (comes back) soon after going into remission. It is less clear if SCT should be used for children whose ALL relapses later (such as more than 6 months or a year) after finishing the initial chemo. These children may respond well to another round of standard-dose chemo.

SCT may also be recommended for children with less common forms of ALL, such as those whose leukemias have the Philadelphia chromosome or those with T-cell ALL that don’t respond well to initial treatment.

Because AML relapses more often than ALL, SCT might be recommended soon after the AML has gone into remission (after the initial chemo treatment), if the child has a donor who can donate stem cells for the transplant. This is especially true if there is a very high risk of relapse. This may be the case with some types of AML or when there are certain gene or chromosome changes in the leukemia cells. There is still some debate about which children with AML need this type of intensive treatment.

If a child with AML relapses after their first round of standard chemo, most doctors will recommend SCT as soon as the child goes into remission again.

In either case, it is important that the leukemia is in remission before getting a SCT. Otherwise, the leukemia is more likely to return.

For most children, SCT is not needed. Newer targeted therapy drugs work well for CML. Transplant is an option when usual treatments do not work well.

JMML is rare and can be difficult to treat. SCT offers the best chance to cure JMML in most cases.

Practical points

A SCT is a complex treatment that can cause life-threatening side effects. If the doctors think your child can benefit from a transplant, the best place to have this done is at a cancer center where the staff has experience with the procedure and with managing the recovery period.

A SCT often requires a long hospital stay and can be very expensive. Even if the transplant is covered by your insurance, your co-pays or other costs could easily amount to many thousands of dollars. It is important to find out what your insurer will cover before the transplant to get an idea of what you might have to pay.

Be sure to talk to your child’s doctor before the transplant to learn about possible long-term side effects your child might have. More information on long-term effects can be found in After Treatment for Childhood Leukemia.

More information about stem cell transplant

To learn more about stem cell transplants, including how they are done and their potential side effects, see Stem Cell Transplant for Cancer.

For more general information about side effects and how to manage them, see Managing Cancer-related Side Effects.

side by side logos for American Cancer Society and American Society of Clinical Oncology

Developed by the American Cancer Society medical and editorial content team with medical review and contribution by the American Society of Clinical Oncology (ASCO).

Aplenc R, Elgarten CW, Choi JK, Meshinchi S. Chapter 17A: Acute Myeloid Leukemia and Myelodysplastic Syndromes. In: Blaney SM, Adamson PC, Helman LJ, eds. Pizzo and Poplack’s Pediatric Oncology. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2021.

National Cancer Institute. Childhood Acute Lymphoblastic Leukemia Treatment (PDQ). 2025. Accessed at https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq on May 7, 2025.

National Cancer Institute. Childhood Acute Myeloid Leukemia Treatment (PDQ). 2025. Accessed at https://www.cancer.gov/types/leukemia/hp/child-aml-treatment-pdq on May 7, 2025.

National Cancer Institute. Childhood Chronic Myeloid Leukemia Treatment (PDQ). 2024. Accessed at https://www.cancer.gov/types/leukemia/hp/child-aml-treatment-pdq/childhood-cml-treatment-pdq on May 7, 2025.

National Cancer Institute. Juvenile Myelomonocytic Leukemia Treatment (PDQ). 2024. Accessed at https://www.cancer.gov/types/leukemia/hp/child-aml-treatment-pdq/childhood-jmml-treatment-pdq on May 12, 2025.

Rau RE, Loh ML. Chapter 17B: Myeloproliferative Neoplasms of Childhood. In: Blaney SM, Adamson PC, Helman LJ, eds. Pizzo and Poplack’s Pediatric Oncology. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2021.

Last Revised: July 22, 2025

American Cancer Society Emails

Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.